Slovakia – Antineoplastic and immunomodulating agents – Lieky ATC skupiny L04AB02, Infliximab parent. 100 mg
Opportunity Score
Confidence: 50%
Complexity: low
15 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
This tender by Všeobecná zdravotná poisťovňa, a.s. (Slovak health insurance company) is an open procedure for a framework agreement to supply Infliximab 100 mg (ATC L04AB02) over 36 months. The estimated total value is €2,667,150. Award is based on lowest price only. Submission is electronic, required in Slovak language, and the deadline is 30 June 2026.
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Open procedure.
- Electronic submission required.
- Submission languages: Slovak (primary); Czech is listed for a second incomplete lot entry, but likely only Slovak required.
Award Criteria
Najnižšia cena
Najnižšia cena
| Criterion | Type |
|---|---|
Najnižšia cena Najnižšia cena | Price |
Buyer
Name
Všeobecná zdravotná poisťovňa, a.s.
Location
Bratislava - mestská časť Petržalka, SVK
Buyer profile
Identifier
35937874
Lots (1)
Supply of Infliximab 100 mg (antineoplastic/immunomodulating agent). Framework agreement for 36 months. Estimated value €2,667,150. Award criteria: lowest price.
Procurement Details
Publication
27 May 2026
Deadline
30 Jun 2026, 08:00
Procedure
open
Contract
supplies
Duration
36 MONTH
Language
SLK, CES
Publication #
364118-2026
Classification
Performance: Slovakia
Documents (2)
Opportunity Score
Confidence: 50%
Complexity: low
15 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation